Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Andrea Centritto, Maria Cappello, Enrica Giuffrida, Antonino Carlo Privitera, Giovita Piccillo, Antonio Magnano, Elisa Vinci, Roberto Vassallo, Antonino Trovatello, Nunzio Belluardo, Emiliano Giangreco, Salvatore Camilleri, Serena Garufi, Carmelo Bertolami, Marco Ventimiglia, Sara Renna, Rosalba Orlando, Giulia Rizzuto, Ambrogio Orlando
Summary: This study aimed to observe the use of infliximab biosimilar SB2 in IBD patients in Sicily. The results indicate that the safety and effectiveness of SB2 appear to be overall similar to those reported for the IFX originator and CT-P13.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
Rosa Lovero, Giuseppe Losurdo, Rosa Federica La Fortezza, Fulvia Terracciano, Giuseppe Biscaglia, Giuseppina Martino, Marianna Nardella, Alfredo Di Leo, Mariabeatrice Principi, Angelo Andriulli, Fabrizio Bossa
Summary: Switching from CT-P13 to SB2 is safe and effective for patients with inflammatory bowel diseases, whether they undergo a single switch or multiple switches between different infliximab compounds.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Noemie Trystram, Vered Abitbol, Jenny Tannoury, Mahaut Lecomte, Julie Assaraf, Georgia Malamut, Charlotte Gagniere, Amelie Barre, Iradj Sobhani, Stanislas Chaussade, Aurelien Amiot
Summary: The study demonstrated that double switching from the originator Infliximab to CT-P13 and then to SB2 did not impair patient beliefs, while the effectiveness, immunogenicity, and safety of anti-TNF therapy remained stable after 54 weeks of follow-up. Patient perspectives remained focused on effectiveness and safety after the switch, rather than on molecular differences between the originator and biosimilars or socioeconomic benefits.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Biotechnology & Applied Microbiology
Fabio Salvatore Macaluso, J. R. Fraser Cummings, Raja Atreya, Jaeyun Choi, Ambrogio Orlando
Summary: The review summarizes available analytical and clinical data on SB2, supporting its equivalence to the reference product across approved indications, including extrapolated indications such as inflammatory bowel disease.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2022)
Article
Gastroenterology & Hepatology
Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D'Inca, Fabiana Zingone, Edoardo Vincenzo Savarino
Summary: The study showed that patients switching from Infliximab originator to SB2 biosimilar were able to maintain clinical and biochemical remission for at least one year. Further data are needed to understand the long-term clinical implications of these findings. Therapeutic optimization may still be necessary despite the switch.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Christine Martinez-Vinson, Anais Lemoine, Yoram Bouhnik, Ben Braithwaite, Audrey Fohlen-Weill, Janet Addison
Summary: The non-interventional study evaluate the response to SB2 therapy in 126 pediatric IBD patients for up to 12 months. The results showed that SB2 provides effective disease control, improved clinical remission rates in naive patients, and no loss of control in switched patients. Growth failure was not observed in IBD patients under SB2 treatment.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2023)
Article
Medicine, Research & Experimental
Yin Su, Jing Li, Chenguang Wang, Xunmin Zhang, Sheng Hou, Huaizu Guo, Chenhui Deng, Lun Ou, Jinwei Wang
Summary: This study investigated the pharmacokinetic characteristics of CMAB008, a biosimilar to infliximab, in healthy subjects and patients with rheumatoid arthritis. The results showed that CMAB008 is bioequivalent to Remicade.
ADVANCES IN THERAPY
(2023)
Article
Medicine, Research & Experimental
Dong W. Kim, Yousun Lee, Geuntae Kim, Sang H. Kim, Dae H. Cho, Jeongmin Choi, Yong H. Kwon, Younjin Park, Wooree Choi, Dong I. Park
Summary: This study confirmed the safety and effectiveness of SB2 in major indications.
ADVANCES IN THERAPY
(2023)
Article
Gastroenterology & Hepatology
Yoram Bouhnik, Bruno Fautrel, Laurent Beaugerie, Anne-Laure Pelletier, Christine Martinez-Vinson, Ulrich Freudensprung, Amira Brigui, Janet Addison, PERFUSE investigators
Summary: This study evaluated the persistence, effectiveness, and safety of SB2 over 12 months in IBD patients. The results showed that more than 75% of IFX-naive patients and more than 90% of patients previously treated with IFX continued with SB2 treatment at 12 months, with no loss of disease control or safety concerns.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Immunology
Chen Yu, Furen Zhang, Yangfeng Ding, Yumei Li, Yi Zhao, Jun Gu, Shuping Guo, Weili Pan, Hongzhong Jin, Qing Sun, Xiaojing Kang, Qinping Yang, Xian Jiang, Zhiqiang Song, Qianjin Lu, Xiaowen Pang, Yehong Kuang, Danqi Deng, Yuzhen Li, Chunlei Zhang, Juan Tao, Liangzhi Xie, Yan Wang, Jieying Wang, Gang Wang
Summary: This study compares the efficacy, safety, and immunogenicity of SCT630 and adalimumab in Chinese patients with moderate to severe plaque psoriasis. The results demonstrate the equivalence of SCT630 and adalimumab in terms of efficacy, safety, and immunogenicity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Nicolino Ruperto, Hermine Brunner, Olga Synoverska, Tracy Ting, Carlos Abud Mendoza, Alberto Spindler, Yulia Vyzhga, Katherine Marzan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Rita Jerath, Daniel J. Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Yonatan Butbul Aviel, Vyacheslav Chasnyk, Melissa Lerman, Kabita Nanda, Heinrike Schmeling, Heather Tory, Yosef Uziel, Diego O. Viola, Holly B. Posner, Keith S. Kanik, Ann Wouters, Cheng Chang, Richard Zhang, Irina Lazariciu, Ming-Ann Hsu, Ricardo M. Suehiro, Alberto Martini, Daniel J. Lovell
Summary: The trial showed that tofacitinib is an effective treatment for patients with polyarticular course JIA. New oral therapies are particularly relevant for children and adolescents, who might prefer to avoid injections.
Article
Dermatology
A. B. Gottlieb, J. F. Merola, K. Reich, F. Behrens, P. Nash, C. E. M. Griffiths, W. Bao, P. Pellet, L. Pricop, I. B. McInnes
Summary: This study compared the efficacy of Secukinumab and adalimumab in patients with PsA and concomitant moderate-to-severe plaque psoriasis. The results showed that Secukinumab demonstrated consistently higher responses across skin endpoints compared to adalimumab.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Review
Medicine, General & Internal
Bruna de Oliveira Ascef, Matheus Oliveira Almeida, Ana Cristina de Medeiros-Ribeiro, Danieli Castro Oliveira de Andrade, Haliton Alves de Oliveira Junior, Patricia Coelho de Soarez
Summary: In this systematic review and meta-analysis, biosimilars of adalimumab, infliximab, and etanercept were found to have clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).
Article
Medicine, General & Internal
Athimalaipet Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Sarka Fingerhutova, Jordi Anton, Zhongkai Wang, Gabriella Meszaros, Joana Araujo, Ran Liao, Stuart Keller
Summary: Baricitinib demonstrated good efficacy and acceptable safety in the treatment of polyarticular juvenile idiopathic arthritis, extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.
Article
Oncology
Daniil L. Stroyakovskiy, Natalya Fadeeva, Marina P. Matrosova, Konstantin G. Shelepen, Grigoriy A. Adamchuk, Bodhisatta Roy, Rajnish Nagarkar, Mahesh Kalloli, Daria Zhuravleva, Georgiy D. Voevodin, Mariya S. Shustova, Fedor Kryukov
Summary: This study demonstrates the therapeutic equivalence of bevacizumab biosimilar BCD-021 and referent bevacizumab drug, which is of significant importance for the first-line treatment of inoperable or advanced non-squamous non-small-cell lung cancer.
Article
Cell Biology
Ewa Kontny, Agnieszka Zielinska, Urszula Skalska, Krystyna Ksiezopolska-Orlowska, Piotr Gluszko, Wlodzimierz Maslinski
Article
Rheumatology
Michael E. Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz-Rosiak, Soo Yeon Cheong, Jeehoon Ghil
ARTHRITIS & RHEUMATOLOGY
(2018)
Article
Rheumatology
Michael E. Weinblatt, Asta Baranauskaite, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz-Rosiak, Inyoung Baek, Jeehoon Ghil
ARTHRITIS & RHEUMATOLOGY
(2018)
Article
Medicine, General & Internal
Jeehoon Ghil, Agnieszka Zielinska, Younju Lee
CURRENT MEDICAL RESEARCH AND OPINION
(2019)
Review
Rheumatology
Roman Yatsyshyn, Olena Zimba, Mykola Bahrii, Bohdana Doskaliuk, Vitalii Huryk
RHEUMATOLOGY INTERNATIONAL
(2019)
Article
Urology & Nephrology
Hana Ciferska, Eva Honsova, Alena Lodererova, Zdenka Hruskova, Michaela Neprasova, Jan Vachek, Miloslav Suchanek, Tomas Zima, Rosanna Coppo, Vladimir Tesar, Jan Novak, Dita Maixnerova
JOURNAL OF NEPHROLOGY
(2020)
Review
Rheumatology
Bohdana Doskaliuk, Olena Zimba, Roman Yatsyshyn, Volodymyr Kovalenko
RHEUMATOLOGY INTERNATIONAL
(2020)
Review
Rheumatology
Bohdana Doskaliuk, Liubomyr Zaiats, Roman Yatsyshyn, Petro Gerych, Nataliia Cherniuk, Olena Zimba
RHEUMATOLOGY INTERNATIONAL
(2020)
Review
Rheumatology
Olena Zimba, Bohdana Doskaliuk, Roman Yatsyshyn, Mykola Bahrii, Marta Hrytsevych
Summary: Granulomatosis with polyangiitis (GPA) is a rare disease with complex clinical presentations and often delayed diagnosis. This report discusses a case study of a 71-year-old female patient with delayed diagnosis of GPA over a period of 40 years, highlighting the importance of recognizing atypical features and avoiding diagnostic errors.
RHEUMATOLOGY INTERNATIONAL
(2021)
Meeting Abstract
Rheumatology
H. Ciferska, K. Pavelcova, J. Vachek, B. Stiburkova
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Bohdana Doskaliuk, Roman Yatsyshyn, Iryna Klishch, Olena Zimba
Summary: The study analyzed COVID-19 related articles in the rheumatology field, providing a comprehensive bibliometric and altmetric analysis. Most studies originated from countries with a high incidence of COVID-19, with rheumatoid arthritis and systemic lupus erythematosus being the most widely discussed rheumatic diseases in relation to COVID-19.
RHEUMATOLOGY INTERNATIONAL
(2021)
Article
Rheumatology
Josef S. Smolen, Jung-Yoon Choe, Nenad Prodanovic, Jaroslaw Niebrzydowski, Ivan Staykov, Eva Dokoupilova, Asta Baranauskaite, Roman Yatsyshyn, Mevludin Mekic, Wieslawa Porawska, Hana Ciferska, Krystyna Jedrychowicz-Rosiak, Agnieszka Zielinska, Younju Lee, Young Hee Rho
ANNALS OF THE RHEUMATIC DISEASES
(2018)